ClinicalTrials.gov record
Terminated Phase 2 Interventional

FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

ClinicalTrials.gov ID: NCT05639543

Public ClinicalTrials.gov record NCT05639543. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 12:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation, Proof-of-Concept Study Evaluating the Safety, Tolerability, Efficacy and Pharmacokinetics of INT-787 in Subjects With Severe Alcohol Associated Hepatitis

Study identification

NCT ID
NCT05639543
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Intercept Pharmaceuticals
Industry
Enrollment
67 participants

Conditions and interventions

Interventions

  • INT-787 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 14, 2022
Primary completion
Feb 9, 2026
Completion
Feb 9, 2026
Last update posted
May 4, 2026

2022 – 2026

United States locations

U.S. sites
20
U.S. states
14
U.S. cities
20
Facility City State ZIP Site status
University of California, San Francisco-Fresno Fresno California 93701
Stanford Healthcare Palo Alto California 94305
UC Davis Medical Center Sacramento California 95817
Clinical Translational Research Site Miami Florida 33136
Tampa General Medical Group Tampa Florida 33606
Rush University Medical Center Chicago Illinois 60612
Mercy Medical Center Baltimore Maryland 21202
Beth Israel Deaconess Medical Center Boston Massachusetts 02215
UMass Memorial Medical Center Worcester Massachusetts 01655
Henry Ford Health System Detroit Michigan 48202
Mayo Clinic Rochester Minnesota 55905
Northwell Health Center for Liver Disease and Transplantation Manhasset New York 11030
Columbia University Medical Center/New York Presbyterian Hospital New York New York 10032
Hospital of the University of Pennsylvania Philadelphia Pennsylvania 19104
Medical University of South Carolina Charleston South Carolina 29425
Vanderbilt Digestive Disease Center Nashville Tennessee 37232
The Liver Institute at Methodist Dallas Medical Center Dallas Texas 75203
Baylor College of Medicine Houston Texas 77030
University of Utah Hospital Salt Lake City Utah 84132
VCU Health Clinical Research Services Unit Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05639543, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05639543 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →